Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections

Antimicrob Agents Chemother. 2019 Oct 22;63(11):e00788-19. doi: 10.1128/AAC.00788-19. Print 2019 Nov.

Abstract

Stenotrophomonas maltophilia is an opportunistic pathogen observed in nosocomial infections. Due to biofilm production and resistance to numerous antimicrobials, eradication is difficult. This study evaluated outcomes for monomicrobial S. maltophilia infections. Seventy-six patients were included, with 45 patients on trimethoprim-sulfamethoxazole and 31 patients on levofloxacin. Overall clinical cure, microbiological eradication, and 28-day mortality were observed in 79%, 82%, and 14% of patients, respectively. The use of trimethoprim-sulfamethoxazole or levofloxacin resulted in high cure rates; however, a trend toward resistance selection with levofloxacin was identified.

Keywords: Stenotrophomonas maltophilia; fluoroquinolone; trimethoprim-sulfamethoxazole.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Female
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Levofloxacin / therapeutic use
  • Male
  • Microbial Sensitivity Tests / methods
  • Middle Aged
  • Retrospective Studies
  • Stenotrophomonas maltophilia / drug effects*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Levofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination